Clinical Trial Update: Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

View source ↗

Summary

Clinical trial evaluating the prognostic impact of decreased serum beta2 microglobulin in the first year of follow-up for myeloproliferative neoplasms; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Snippet

Sponsor: University Hospital, Brest | Conditions: Myeloproliferative Neoplasm | Status: ACTIVE_NOT_RECRUITING